Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Other Non-Current Assets (2024 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Other Non-Current Assets for 8 consecutive years, with $5.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Other Non-Current Assets changed 0.0% to $5.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $5.0 million, a 0.0% change, with the full-year FY2024 number at $5.0 million, changed N/A from a year prior.
  • Other Non-Current Assets was $5.0 million for Q3 2025 at Madrigal Pharmaceuticals, roughly flat from $5.0 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $5.0 million in Q2 2024 to a low of $5.0 million in Q2 2024.